Publication date: November 2026 Source: Journal of Thoracic Oncology, Volume 21, Issue 11 Author(s): Ana Baramidze, Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Davit Giorgadze, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Yuntong Li, Debra A.G. McIntyre, Xue Jia, Javier Perez, Manika Kaul, Israel Lowy, Jean-Francois Pouliot, Stefanie Chua, Eric Kim
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial. // Journal of Thoracic Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1556086426004338?dgcid=rss_sd_all
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial. Journal of Thoracic Oncology. https://www.sciencedirect.com/science/article/pii/S1556086426004338?dgcid=rss_sd_all
“Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.” Journal of Thoracic Oncology.
@article{article56010,
title = {Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial},
journal = {Journal of Thoracic Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1556086426004338?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment